19240-24-5

Upstream product

• 6206-42-4 N-benzyloxycarbonylglycyl-L-phenylalanine methyl ester 
• 7524-50-7 methyl (2S)-2-amino-3-phenylpropanoate hydrochloride 
• 4833-87-8 2?(1,3?dioxoisoindolin?2?yl)acetyl methyl phenylalaninate 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 1170-76-9 Z-Gly-(L)-Phe 
• 63-91-2 L-phenylalanine 
• 2577-90-4 methyl (2S)-2-amino-3-phenylpropanoate 
• 106624-70-8 methyl (2S)-2-[[2-(t-butoxycarbonylamino)acetyl]amino]-3-phenylpropanoate 

Downstream Products

• 63631-32-3 (S)-methyl 12-benzyl-2,2-dimethyl-4,7,10-trioxo-3-oxa-5,8,11-triazatridecan-13-oate 
• 58822-25-6 Leu-enkephalin 
• 60117-24-0 H-Tyr-Gly-Gly-Phe-Leu-NH₂ 
• 61131-29-1 N-glycyl>-L-3-phenylalanine methyl ester hydrochloride 
• 501082-71-9 Boc-Tyr(2,6-Cl₂Bzl)-Gly-Gly-Phe-OMe 
• 501082-72-0 Boc-Tyr(2,6-Cl₂Bzl)-Gly-Gly-Phe-OH 
• 501082-79-7 Boc-Tyr(2,6-Cl₂Bzl)-Gly-Gly-Phe-Leu-OMe 
• 501082-80-0 Boc-Tyr(2,6-Cl₂Bzl)-Gly-Gly-Phe-Leu-NH₂ 
• 143050-69-5 Boc-Tyr(CLz)-Gly-Gly-Phe-Leu-OH 
• 501083-33-6 estrone-3-O-CH₂CO-Tyr-Gly-Gly-Phe-Leu-OH 
• 501083-34-7 estrone-3-O-CH₂CO-Tyr-Gly-Gly-Phe-Leu-OMe 
• 501082-91-3 2-[2-(2-{2-[2-tert-butoxycarbonylamino-3-(4-hydroxy-phenyl)-propionylamino]-acetylamino}-acetylamino)-3-phenyl-propionylamino]-4-methyl-pentanoic acid 3-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl ester 
• 501083-16-5 estrone-3-O-CH₂CO-Tyr(2,6-dichlorobenzyl)-Gly-Gly-Phe-Leu-OMe 

Relevant academic research and scientific papers

Rhodium(III)-Catalyzed C-H Alkenylation: Access to Maleimide-Decorated Tryptophan and Tryptophan-Containing Peptides

Maleimide is widely applied in many fields, especially in antibody-drug conjugations and peptide drugs. Herein, we develop a strategy for the C-H alkenylation of tryptophan and tryptophan-containing peptides, providing a synthetic route of decorating male

Peptide-Catalyzed Fragment Couplings that Form Axially Chiral Non-C2-Symmetric Biaryls

We have demonstrated that small, modular, tetrameric peptides featuring the Lewis-basic residue β-dimethylaminoalanine (Dmaa) are capable of atroposelectively coupling naphthols and ester-bearing quinones to yield non-C2-symmetric BINOL-type scaffolds with good yields and enantioselectivity. The study culminates in the asymmetric synthesis of backbone-substituted scaffolds similar to 3,3′-disubstituted BINOLs, such as (R)-TRIP, with good (94:6 e.r.) to excellent (>99.9:0.1 e.r.) enantioselectivity after recrystallization, and a diastereoselective net arylation of the minimally modified nonsteroidal anti-inflammatory drug (NSAID) naproxen.

Novel thiazolidinedione-5-acetic-acid-peptide hybrid derivatives as potent antidiabetic and cardioprotective agents

Thiazolidinediones (TZDs) are one of the important clinically established antidiabetic agents. Amino-acid and peptides have an advantage of better target selectivity and specificity. As hybrids, they also improved absorption and showed better bioavailability, which in turn makes them safer. Hence, here an effort has been made to synthesize hybrids of thiazolidinedione with amino-acids and peptides and evaluate their antidiabetic and cardioprotective effect in streptozotocin-nicotinamide (STZ-NA) induced Type 2 diabetes mellitus (T2DM) rat models. A series of 14 thiazolidinedione-5-acetic acid hybrids with of different amino-acids and peptide combinations were synthesized, characterized and further screened for antidiabetic and cardioprotective activity. Among all, six compounds T1 (SSDMA1), T4 (SSDMA4), T5 (SSDMA5), T7 (SDMA13), T9 (SSDMA15) and T13 (SSDMA49) showed better antioxidant activity and comparable % glucose uptake by yeast cells. Hence, the in vivo antidiabetic screening was done for these six compounds. Among all six T1, T7, T13 showed significant blood glucose level decrease compared to standard pioglitazone HCl. Also T1, T7 and T13 showed better antioxidant activity with lower IC50 value than standard ascorbic acid, and hence in vivo cardioprotective studies were done for these. The ECG studies showed that T1 (SSDMA1) and T7 (SSDMA13) were better effective than SDMA49 (T13) in restoring the normal functioning of the heart, thus may help in preventing the development of diabetic cardiomyopathy (DCM) and controlling T2DM.

Environmentally benign peptide synthesis using liquid-assisted ball-milling: Application to the synthesis of Leu-enkephalin

This paper describes an original methodology for peptide bond synthesis avoiding toxic solvents and reactants. Ball-milling stoichiometric amounts of Boc-protected α-amino acid N-carboxyanhydrides (Boc-AA-NCA) or Boc-protected α-amino acid N-hydroxysuccin

Studies on the synthesis and anti-Osteoporosis of estrogen-GHRPs linkers.

The linkers of estrogen-GHRPs were prepared by the combination of estradiol, estrone, TyrGlyGlyPheLeuOH, and TyrGlyGlyPheLeuOH. Their anti-osteoporosis effect was evaluated by analyzing the data, for instance the weight of the body, femur, femur ash, the content of calcium and phosphor in the femur, the content of calcium and ALP activity in the serum, obtained from the corresponding bioassay in vivo. The results indicated that the anti-osteoporosis potency for estradiol, estrone, TyrGlyGlyPheLeuOH and TyrGlyGlyPheLeuNH(2) may be totally enhanced each other via the corresponding linkers.

An Improvment of the Anderson Test by the Use of High Performance Liquid Chromatography

The replacement of the N-benzyloxycarbonyl (Z) group in the Anderson peptide (Z-Gly-L/D-Phe-Gly-OEt) by Z-L-Ala and the subsequent separation of the diastereomers of the resulting tetrapeptide by reversed-phase HPLC offer a more convenient version with higher accuracy to the original Anderson test for studying racemization in peptide synthesis.